Compound 506U78 (NSC 686673) [nelarabine] in Patients With Relapsed or Refractory T-Cell ALL [acute lymphoblastic leukaemia] or T-Cell Lymphoblastic Lymphoma

Trial Profile

Compound 506U78 (NSC 686673) [nelarabine] in Patients With Relapsed or Refractory T-Cell ALL [acute lymphoblastic leukaemia] or T-Cell Lymphoblastic Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2013

At a glance

  • Drugs Nelarabine (Primary)
  • Indications Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2007 Status changed from in progress to completed.
    • 31 Oct 2006 Status change
    • 07 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top